These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1304 related items for PubMed ID: 10815117

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
    Park SK, Kim JH, Kang H, Cho JS, Smego RA.
    Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Clinical and operational value of the extensively drug-resistant tuberculosis definition.
    Migliori GB, Besozzi G, Girardi E, Kliiman K, Lange C, Toungoussova OS, Ferrara G, Cirillo DM, Gori A, Matteelli A, Spanevello A, Codecasa LR, Raviglione MC, SMIRA/TBNET Study Group.
    Eur Respir J; 2007 Oct; 30(4):623-6. PubMed ID: 17690121
    [Abstract] [Full Text] [Related]

  • 25. Low levels of drug resistance amidst rapidly increasing tuberculosis and human immunodeficiency virus co-epidemics in Botswana.
    Kenyon TA, Mwasekaga MJ, Huebner R, Rumisha D, Binkin N, Maganu E.
    Int J Tuberc Lung Dis; 1999 Jan; 3(1):4-11. PubMed ID: 10094163
    [Abstract] [Full Text] [Related]

  • 26. High rates of multidrug-resistant and rifampicin-resistant tuberculosis among re-treatment cases: where do they come from?
    Ragonnet R, Trauer JM, Denholm JT, Marais BJ, McBryde ES.
    BMC Infect Dis; 2017 Jan 06; 17(1):36. PubMed ID: 28061832
    [Abstract] [Full Text] [Related]

  • 27. Epidemiology of drug-resistant tuberculosis in New Jersey from 1991 to 1995.
    Liu Z, Shilkret KL, Finelli L.
    Int J Epidemiol; 1998 Feb 06; 27(1):121-6. PubMed ID: 9563705
    [Abstract] [Full Text] [Related]

  • 28. Treatment outcomes of retreated patients with isoniazid/rifampicin resistant pulmonary tuberculosis.
    Zhang L, Han X, Ge Q, Shu W, Sun Y, Gao J, Xie S, Wang J, Gao W.
    BMC Infect Dis; 2024 Jan 02; 24(1):7. PubMed ID: 38166793
    [Abstract] [Full Text] [Related]

  • 29. First-line tuberculosis drug resistance patterns and associated risk factors in Germany, 2008-2017.
    Glasauer S, Altmann D, Hauer B, Brodhun B, Haas W, Perumal N.
    PLoS One; 2019 Jan 02; 14(6):e0217597. PubMed ID: 31188848
    [Abstract] [Full Text] [Related]

  • 30. Drug-resistance patterns of Mycobacterium tuberculosis strains and associated risk factors among multi drug-resistant tuberculosis suspected patients from Ethiopia.
    Mesfin EA, Beyene D, Tesfaye A, Admasu A, Addise D, Amare M, Dagne B, Yaregal Z, Tesfaye E, Tessema B.
    PLoS One; 2018 Jan 02; 13(6):e0197737. PubMed ID: 29864118
    [Abstract] [Full Text] [Related]

  • 31. Drug-resistant tuberculosis in the Dominican Republic: results of a nationwide survey.
    Espinal MA, Báez J, Soriano G, Garcia V, Laszlo A, Reingold AL, Sanchez S.
    Int J Tuberc Lung Dis; 1998 Jun 02; 2(6):490-8. PubMed ID: 9626607
    [Abstract] [Full Text] [Related]

  • 32. Drug resistance pattern in Mycobacterium tuberculosis to the first line drugs of pulmonary tuberculosis patients at Hazara Region, Pakistan.
    Jan F, Wali S, Sadia S, Akbar MT, Akbar HS, Ahmad W, Ahmad M, Khalid A.
    Tuberk Toraks; 2018 Mar 02; 66(1):26-31. PubMed ID: 30020038
    [Abstract] [Full Text] [Related]

  • 33. [Multiple drug resistance: a threat for tuberculosis control].
    Cardoso EM.
    Rev Panam Salud Publica; 2004 Jul 02; 16(1):68-73. PubMed ID: 15333267
    [Abstract] [Full Text] [Related]

  • 34. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.
    Pablos-Méndez A, Raviglione MC, Laszlo A, Binkin N, Rieder HL, Bustreo F, Cohn DL, Lambregts-van Weezenbeek CS, Kim SJ, Chaulet P, Nunn P.
    N Engl J Med; 1998 Jun 04; 338(23):1641-9. PubMed ID: 9614254
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Revised Category II regimen as an alternative strategy for retreatment of Category I regimen failure and irregular treatment cases.
    Tabarsi P, Chitsaz E, Tabatabaei V, Baghaei P, Shamaei M, Farnia P, Marjani M, Kazempour M, Mansouri D, Masjedi MR, Velayati AA.
    Am J Ther; 2011 Sep 04; 18(5):343-9. PubMed ID: 20535008
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis.
    Seung KJ, Gelmanova IE, Peremitin GG, Golubchikova VT, Pavlova VE, Sirotkina OB, Yanova GV, Strelis AK.
    Clin Infect Dis; 2004 Nov 01; 39(9):1321-8. PubMed ID: 15494909
    [Abstract] [Full Text] [Related]

  • 39. Trends and characteristics of drug-resistant tuberculosis in rural Shandong, China.
    Tao NN, He XC, Zhang XX, Liu Y, Yu CB, Li HC.
    Int J Infect Dis; 2017 Dec 01; 65():8-14. PubMed ID: 28958922
    [Abstract] [Full Text] [Related]

  • 40. Prevalence and genetic profiles of isoniazid resistance in tuberculosis patients: A multicountry analysis of cross-sectional data.
    Dean AS, Zignol M, Cabibbe AM, Falzon D, Glaziou P, Cirillo DM, Köser CU, Gonzalez-Angulo LY, Tosas-Auget O, Ismail N, Tahseen S, Ama MCG, Skrahina A, Alikhanova N, Kamal SMM, Floyd K.
    PLoS Med; 2020 Jan 01; 17(1):e1003008. PubMed ID: 31961877
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 66.